âïž ðïž ã³ãããç¶²èã®ãæé€å±ããä¹ã£åãââ倱æã«ã€ãªããé·æçãªã¹ã¯ã®å¯èœæ§
ã³ãããç®ã«å±ãããšã¯ç¥ãããŠãããããããç¶²èã®äžçªéèŠãªçްèã«ãäœã¿çããŠå¢æ®ãããããšãå®éšã§èšŒæããããUCLAïŒã«ãªãã©ã«ãã¢å€§åŠããµã³ãŒã«ã¹æ ¡ïŒã®ç ç©¶ããŒã ããããACE2ãæã€ããŠã¹ãšããç¶²è现èã䜿ã£ãŠå®éšããçµæãSARS-CoV-2ã¯ç¶²èè²çŽ äžç®ïŒRPEïŒãšãã现èã«ææãã墿®ããæ©èœãå£ããççãåºããŠããããã®ççã®ãã¿ãŒã³ã¯ãå éœ¢é»æå€æ§ïŒAMDïŒââå é²åœã«ããã倱æã®äž»ãªåå ââã®åæãšé©ãã»ã©äŒŒãŠããã
ð¬ äœãããã
- UCLAã®çŒç§ãšå ç§ã®ååããŒã ã宿œ
- 2ã€ã®å®éšç³»ã䜿ã£ãïŒ
- in vivoïŒçäœå ïŒïŒããACE2ãæã€ãã©ã³ã¹ãžã§ããã¯ããŠã¹ïŒAC70ãšK18ã®2系統ïŒã«éŒ»ããã³ãããŠã€ã«ã¹ïŒåæåïŒãæ¥çš®
- in vitroïŒå¹é€çްèïŒïŒããèæ§å¹¹çŽ°èç±æ¥RPEïŒhES-RPEïŒãããèå RPEïŒhfRPEïŒãARPE-19çŽ°èæ ªã«åæåã»ãã«ã¿ã»ãªãã¯ãã³ã®3å€ç°æ ªãææããã
- 以äžã調ã¹ãïŒ
- ãŠã€ã«ã¹ãRPEã«å°éããŠææãããïŒå ç«èå ã»é»åé¡åŸ®é¡ïŒ
- RPE现èã§ãŠã€ã«ã¹ã墿®ãããïŒTCID50ã¢ãã»ã€ïŒ
- RPEã®åœ¢æ ãã©ãå€ãããïŒé»åé¡åŸ®é¡ã»ãã¡ãã€ãžã³æè²ïŒ
- RPEã®ããªã¢æ©èœïŒTEER枬å®ïŒ
- RPEã®è²ªé£èœïŒèŠçްèå€ç¯ã®æ¶åèœåïŒ
- è£äœæŽ»æ§åãšççæ§ãµã€ãã«ã€ã³ã®ç£ç
- ã¬ã³ããŠã€ã«ã¹ã䜿ã£ãŠãã¹ãã€ã¯ã¿ã³ãã¯è³ªåç¬ãããã³ãŠã€ã«ã¹ã¿ã³ãã¯è³ªEãšORF3aã®å¹æãåé¢ããŠèª¿ã¹ã
ð¯ äœãåãã£ãã
â ã³ãããŠã€ã«ã¹ã¯éŒ»ããå ¥ã£ãŠãç¶²èã®RPEã«å±ãã
- AC70ããŠã¹ïŒããACE2ãç¶²èã«çºçŸãã系統ïŒã«éŒ»ãããŠã€ã«ã¹ãå ¥ãã
- 5æ¥åŸã«RPEã§ãŠã€ã«ã¹ã®æ žé žã¿ã³ãã¯è³ªãæ€åºããã
- é»åé¡åŸ®é¡ã§RPE现èã®é 端éšã«çµã¿ç«ãŠããããŠã€ã«ã¹ç²åã確èªããã
- K18ããŠã¹ïŒå¥ã®ç³»çµ±ïŒã§ã¯RPEææãèŠãããªãã£ãââACE2ã®çºçŸãã¿ãŒã³ã®éããåå
- èºã®ãŠã€ã«ã¹éãšRPEææã®æç¡ã¯çžé¢ããªãã£ãââãèºãéçã§ãç®ã«ææããªã人ãããã°ãèºã軜çã§ãç®ã«ææãã人ããããå¯èœæ§
â¡ ããRPE现èã§ããŠã€ã«ã¹ã墿®ãã
- ããRPE现èã¯ACE2ãšTMPRSS2ïŒãŠã€ã«ã¹ã®äŸµå ¥ã«å¿ èŠãªå容äœãšé µçŽ ïŒãçºçŸããŠãã
- åæåã»ãã«ã¿ã»ãªãã¯ãã³ã®3å€ç°æ ªãã¹ãŠãRPE现èã«ææããŠå¢æ®ãã
- ãŠã€ã«ã¹ã¯äž»ã«RPEã®é 端éšïŒèŠçްèã«æ¥ããåŽïŒããäŸµå ¥ããé 端éšããæŸåºããã
- ææåŸ10æ¥çµã£ãŠããŠã€ã«ã¹ãæ€åºããç¶ããââRPEã¯ããŠã€ã«ã¹ã®å·¥å Žãã«ãªãåŸã
- ãªãã¯ãã³ã¯åæåããåæã®ç£çéãäœããã10æ¥åŸã«ã¯åçã¬ãã«ã«éãã
⢠RPEã®åœ¢æ ãå£ããã
- åæåææçްèïŒé 端ã®åŸ®çµšæ¯ïŒèŠçްèãšéä¿¡ããæ¯ïŒã倱ããã现èãèšæœ€
- ãªãã¯ãã³ææçްèïŒå£æ»ãèµ·ãã现èãå€ããçŽ°èæ®éªžã®äžã«ãŠã€ã«ã¹ç²åãæ®ã£ãŠãã
- ã¹ãã€ã¯ã¿ã³ãã¯è³ªã ãã§ãïŒç°åžžãªèçªåºã现èç¢çãåºåºæ²çç©ãåºçŸ
- ãŠã€ã«ã¹ã¿ã³ãã¯è³ªEãšORF3aã ãã§ãïŒã¹ãã¬ã¹ç·ç¶ã®å¢å ã埮絚æ¯ã®æžå°ã现èå 空èã®åºçŸ
⣠RPEã®ããªã¢æ©èœãå£ãã
- RPEã¯ãå€åŽã®è¡æ¶²ç¶²èé¢éãã圢æããââèŠçްèãšè¡ç®¡ã®éã®é¢æ
- ãªãã¯ãã³ææã§TEERïŒé»æ°æµæïŒããªã¢ã®åŒ·ãïŒãäžéæ§ã«ææã«äœäž
- ãã¹ãŠã®å€ç°æ ªã§ãææåããTEERãäžãããçŸè±¡ã芳å¯ããã
- ã¿ã€ããžã£ã³ã¯ã·ã§ã³ã®ã¿ã³ãã¯è³ªZO-1ã®çºçŸãæžå°ããå±åšãä¹±ãã
- ããã¯èšåºã§å ±åãããŠãããé»ææµ®è «ãã®ã¡ã«ããºã ã説æããå¯èœæ§
†RPEã®ãæé€ãæ©èœãå£ãã
- RPEã¯æ¯æ¥èŠçްèã®å 端ïŒå€ç¯ïŒãé£ã¹ãŠæ¶åããââãããæ ããšèŠçްèãæ»ã¬
- ã¹ãã€ã¯ã¿ã³ãã¯è³ªãRPEã«äŸµå ¥ãããšãèŠçްèå€ç¯ã®ãçµåããææã«æžå°
- åå ïŒÎ±vβ5ã€ã³ãã°ãªã³ïŒèŠçްèå€ç¯ãæãŸããããã®å容äœïŒããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®äŸµå ¥ã«ã䜿ãããŠãããŸããçºçŸãæžã
- ãŠã€ã«ã¹ã¿ã³ãã¯è³ªEãšORF3aããããšãé£ã¹ãŠå ¥ããå€ç¯ã®ãæ¶åããé ãã
- ORF3aã¯ã©ã€ãœãŸãŒã ïŒæ¶åå·¥å ŽïŒã®æ©èœãé»å®³ããããšãç¥ãããŠããââRPEã®æ¶åå·¥å Žãæ¢ãŸã
⥠è£äœãåºç¯å²ã«æŽ»æ§åãã
- RPEã®å°æ°ã®çްèã«ãããŠã€ã«ã¹ãææããŠããªããŠããè£äœæåC3bãšC5b-9ïŒè䟵襲è€åäœïŒãRPEå šäœã«åºãèç©ãã
- ã€ãŸããææãã现èããççã®åå³ãåºãŠãåšå²ã®çްèã«ãè£äœãéãŸããââææã屿çã§ãççã¯åºåç
- ããã¯å éœ¢é»æå€æ§ïŒAMDïŒã®ç æ ãšé©ãã»ã©äŒŒãŠãã
⊠ççæ§ãµã€ãã«ã€ã³ãé·æéç£çããç¶ãã
- åæåææïŒIL-1βãIL-6ãIL-8ãTNF-αã6ã10æ¥åŸãŸã§äžæãç¶ãã
- ãªãã¯ãã³ææïŒIL-6ãšIL-8ã¯8æ¥ç®ããé ããŠäžæããé·æéæç¶
- ãªãã¯ãã³ã¯èºã§ã¯ã軜çãã ããç®ã§ã¯ãé ããŠæ¥ãé·æççããèµ·ããå¯èœæ§
- ãããã®ãµã€ãã«ã€ã³ã¯AMDã®ç æ ã§ãç£çããããã®ãšåã
ð¡ äœãæå³ããã
ãç®ã«ãã³ãããå ¥ããã¯æ¯å©ã§ã¯ãªã
- 錻ããå ¥ã£ããŠã€ã«ã¹ãè¡æµãç¥çµçµè·¯ããéããŠç¶²èã«å±ã
- èºã®éç床ãšç®ã®ææã¯é¢ä¿ãªãââ軜çã§ãç®ã«å±ãå¯èœæ§
- RPEã¯ACE2ãé«çºçŸããŠããããŠã€ã«ã¹ã®ãæ Œå¥œã®æšçã
RPEã¯ãèŠçްèã®åœç¶±ã
- RPEã¯èŠçްèã®å€ç¯ãæ¯æ¥é£ã¹ãŠæ¶åããèŠçްèãå¥åº·ã«ä¿ã€
- ããªã¢ãšããŠäžèŠãªç©è³ªã®äŸµå ¥ãé²ã
- ãã®2ã€ã®æ©èœãã³ããææã§å£ããââèŠçްèãã逿»ãããå¯èœæ§
ãæ¶åå·¥å Žã®å æ ããäžçªæã
- ãŠã€ã«ã¹ãRPEã®ã©ã€ãœãŸãŒã ïŒæ¶åå·¥å ŽïŒãä¹ã£åã£ãŠèªåã®å¢æ®ã«å©çšãã
- èŠçްèã®å€ç¯ãæ¶åãããã«æºãŸãââãããAMDã®åæç æ ãšåã
- ORF3aã¿ã³ãã¯è³ªããã®ãä¹ã£åããã®äž»ç¯
è£äœã®åºå掻æ§åãAMDã®åŒãéã«ãªãå¯èœæ§
- ææçްèãå°æ°ã§ããè£äœãRPEå šäœã«åºãã
- è£äœã®æç¶ç掻æ§åã¯é·æã³ããïŒlong COVIDïŒã®ç¹åŸŽã§ããã
- AMDã®æå€§ã®éºäŒçãªã¹ã¯å åã¯è£äœå åHïŒCFHïŒã®å€ç°ââè£äœã®å¶åŸ¡ãå£ãããšAMDã«ãªã
- ã³ããææããè£äœã®æŽèµ°ããåŒãèµ·ãããAMDã®çºçãå éããå¯èœæ§
HIVã®åäŸããã
- HIVææè ã§ã¯AMDãè¥ã幎霢ããå¢ããããšãç¥ãããŠãã
- ã¡ã«ããºã ã¯ãèªç¶å ç«ã®æç¶ç掻æ§åã
- ã³ããã¯HIVããã¯ããã«å€ãã®äººã«ææããŠããââåãã¡ã«ããºã ãèµ·ããã°ãå ¬è¡è¡çäžã®åœ±é¿ã¯æ¡éã
ãªãã¯ãã³ïŒè»œçãã¯ç®ã«é¢ããŠã¯åœãŠã¯ãŸããªããããããªã
- èºã§ã¯ãªãã¯ãã³ã¯è»œçã ããRPEã§ã¯é ããŠåŒ·ãççãèµ·ãã
- IL-6ãšIL-8ã®æç¶çç£çã¯ãé·æã®ç®ã®ççããæå³ãã
- å€ç°æ ªã«ãã£ãŠãã©ãããã¡ãŒãžãåãããããéãå¯èœæ§
é·æçãªèŠåãžã®åœ±é¿ã¯ãŸã èŠããªã
- AMDã¯äœå幎ããããŠé²è¡ããç æ°
- ã³ããææãRPEã«äžãããã¡ãŒãžãã5幎åŸã10幎åŸã20幎åŸã«ã©ãçŸããã
- çŸæç¹ã§ã¯ãå¯èœæ§ã®èŠåãã§ããã確蚌ã§ã¯ãªã
â ïž æ³šæç¹
- ããŠã¹å®éšãšå¹é€çްèå®éšã®çµã¿åãããããã§ã®çŽæ¥èšŒæã§ã¯ãªãããã ãããRPE现èã䜿ã£ãin vitroå®éšã§ããŠã¹ã®çµæãè£ä»ããŠãã
- AC70ããŠã¹ã¯ç¹æ®ãªç³»çµ±ãCRB1å€ç°ãæã£ãŠãããè ž-ç¶²èé¢éã®åŒ±ããRPEææãå©ããå¯èœæ§ããããK18ããŠã¹ã§ã¯RPEææãèŠãããªãã£ã
- æ¥æ§æïŒ5ã10æ¥ïŒã®è©äŸ¡ã®ã¿ãé·æçãªRPEãžã®åœ±é¿ã¯è¿œè·¡ããŠããªããAMDã®ãããªå€æ§ã«ã¯äœå¹Žãããã
- ææçµè·¯ãç¹å®ãããŠããªããè¡æµããèŠç¥çµããã®éè¡æ§äŒæããã°ã«ãŒãã³ã°è¡åã«ããè§èçµè·¯ãã¯äžæ
- ãªãã¯ãã³ã®ããŒã¿ã¯BA.1ã®ã¿ãçŸåšäž»æµã®XBBãJN.1ãªã©ã§ã¯ç°ãªãå¯èœæ§ããã
- RPEçŽ°èæ ªã®éçãARPE-19ã¯å¹é€çްèã§ãããçäœå ã®RPEãšã¯å®å šã«åãã§ã¯ãªã
- è£äœæŽ»æ§åãšAMDã®å æé¢ä¿ã¯æšæž¬ãè£äœã䌌ãŠãããããšãã£ãŠãå¿ ãAMDãå éããããã§ã¯ãªã
- èšåºç蚌æ ããŸã äžè¶³ãã³ããææè ã§AMDãå¢ããŠãããšããç«åŠããŒã¿ã¯çŸæç¹ã§éå®ç
- ãå ¬è¡è¡çäžã®åœ±é¿ãã¯èè ã®æšæž¬ãå®éã®ãªã¹ã¯ã®å€§ããã¯ä»åŸã®çžŠæç ç©¶ã§æããã«ããå¿ èŠããã
ð§© äžèšã§èšããš
UCLAã®ããŒã ããããACE2ãæã€ããŠã¹ãšããç¶²è现èã䜿ã£ãŠå®éšããçµæãSARS-CoV-2ã¯éŒ»ããå ¥ã£ãŠãç¶²èã®è²çŽ äžç®ïŒRPEïŒã«å°éããŠææãã10æ¥ä»¥äžã«ããã墿®ãç¶ããããŠã€ã«ã¹ã¯RPEã®ããªã¢æ©èœãšèŠçްèå€ç¯ã®è²ªé£ã»æ¶åæ©èœãå£ããè£äœãåºç¯å²ã«æŽ»æ§åããIL-1βãIL-6ãIL-8ãTNF-αãªã©ã®ççæ§ãµã€ãã«ã€ã³ãé·æéç£çãããããã®ççãã¿ãŒã³ã¯å éœ¢é»æå€æ§ïŒAMDïŒã®åæç æ ãšé©ãã»ã©äŒŒãŠãããã³ããææãAMDã®çºçãå éããå¯èœæ§ããããšèè ã¯èŠåãããHIVææã§AMDãè¥å¹Žçºçããããšãç¥ãããŠããããã³ããã¯ã¯ããã«å€ãã®äººã«ææããŠããããã圱é¿ãããã°å ¬è¡è¡çäžã®èŠæš¡ã¯æ¡éãã«ãªãããã ãããŠã¹ãšå¹é€çްèã®å®éšã§ãããæ¥æ§æã®ã¿ã®è©äŸ¡ã§ãé·æçãªèŠåãžã®åœ±é¿ã¯æšæž¬ã®åãåºãªãã
ð è«ææ å ±
- ã¿ã€ãã«: Productive infection of the retinal pigment epithelium by SARS-CoV-2: Initial effects and consideration of long-term consequences
- èè : Nan W. Hultgren, Anton Petcherski, Simona Torriano, et al.
- æ²èŒèª: PNAS Nexus (2024)
- DOI: 10.1093/pnasnexus/pgae500
ã¡ãã»ãŒãžïŒæè¿ç§ã¯ãèªäœã¢ããªã®migaã§éå€ãªããšããã³ã°ã³ããã®ææ°ç ç©¶ãªã©ãåããŠããŸãããµã€ã³ã¢ããããŠã誰ã§ãå©çšã§ããŸãããã²ãåå ãã ãããã¢ã«ãŽãªãºã ããªãã£ãæã®Twitterã®ãããªæãã§ãèªåã®ã¿ã€ã ã©ã€ã³ãäœã£ãŠç¥ãåããæåŸ ããããšãåºæ¥ãŸãã
ãèå³ã®ããæ¹ã¯ãã¡ããðïž